<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Disease Modeling References</title>
  
  <!-- Bootstrap CSS -->
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <link rel="stylesheet" href="../../styles.css">

  <!-- MathJax for LaTeX -->
  <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
  <script id="MathJax-script" async
    src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js">
  </script>

  <style>
    body {
      background-color: #f5f5f5;
      color: #2c2c2c;
      font-family: 'Open Sans', sans-serif;
      padding: 2rem;
    }
    h1, h2, h3 {
      font-family: 'Playfair Display', serif;
    }
    .highlight {
      color: #8e5e3b;
      font-weight: 600;
    }
    .definition-table {
      width: 100%;
      border-collapse: collapse;
      margin: 1.5rem 0;
    }
    .definition-table th, .definition-table td {
      border: 1px solid #ccc;
      padding: 0.75rem;
      text-align: left;
    }
    .definition-table th {
      background-color: #eee;
    }
    code {
      background-color: #eee;
      padding: 2px 6px;
      border-radius: 4px;
    }
    pre {
      background-color: #f0f0f0;
      padding: 1rem;
      border-radius: 5px;
      overflow-x: auto;
    }
  </style>
</head>

<body>
      <!-- Sticky Navigation Bar -->
<nav class="navbar navbar-expand-lg navbar-light bg-light fixed-top shadow-sm">
  <div class="container">
    <a class="navbar-brand fw-bold" href="index.html">Veronica Scerra Data Science</a>
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarContent"
      aria-controls="navbarContent" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>
    
    <div class="collapse navbar-collapse" id="navbarContent">
      <ul class="navbar-nav ms-auto mb-2 mb-lg-0">
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#about">About</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#projects">Projects</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#skills">Skills</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="../../index.html#contact">Contact</a>
        </li>
      </ul>
    </div>
  </div>
</nav>
 <div style="height: 72px;"></div> <!-- Global offset -->

  <div class="container">
    <a href="disease_modeling.html" class="btn btn-outline-secondary mb-4">&larr; Back to Disease Modeling</a>

    <section id="references">
  <h1>Disease Modeling References</h1>
  <p class="lead">A comprehensive bibliography organized by project, documenting the epidemiological literature, mathematical methods, and data sources that informed each modeling study.</p>

  <!-- General/Cross-Project References -->
  <h2 class="mt-5 mb-3" style="border-bottom: 2px solid #8e5e3b; padding-bottom: 0.5rem;">General Methodology</h2>
  <p class="text-muted">Foundational texts and methods applicable across multiple projects.</p>
  
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Brauer, F., van den Driessche, P., Wu, J (Eds.) (2008).</strong>
      <a href="https://doi.org/10.1007/978-3-540-78911-6" target="_blank" rel="noopener noreferrer">
        <em>Mathematical Epidemiology</em>
      </a>.
      Springer.
      <div class="text-muted small ms-3">Comprehensive textbook on compartmental modeling, parameter estimation, and epidemic theory.</div>
    </li>

    <li class="mb-3">
      <strong>Storn, R., Price, K. (1997).</strong>
      <a href="https://www.cp.eng.chula.ac.th/~prabhas//teaching/ec/ec2012/storn_price_de.pdf" target="_blank" rel="noopener noreferrer">
        <em>Differential Evolution - A Simple and Efficient Heuristic for Global Optimization over Continuous Spaces</em>
      </a>.
      Journal of Global Optimization, 11, 341-359.
      <div class="text-muted small ms-3">Global optimization algorithm used for parameter estimation in the Cuba HIV/AIDS model.</div>
    </li>
  </ul>

  <!-- Cuban HIV/AIDS Project -->
  <h2 class="mt-5 mb-3" style="border-bottom: 2px solid #8e5e3b; padding-bottom: 0.5rem;">Cuban HIV/AIDS Model</h2>
  <p class="text-muted">Compartmental modeling of contact tracing effectiveness (1986-2000).</p>
  
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>De Arazoza, H., Lounes, R. (2002).</strong>
      <a href="https://helios2.mi.parisdescartes.fr/~lounes/rapports/ima2002.pdf" target="_blank" rel="noopener noreferrer">
        <em>A non-linear model for a sexually transmitted disease with contact tracing</em>
      </a>.
      IMA Journal of Mathematics Applied in Medicine and Biology, 19, 221-234.
      <div class="text-muted small ms-3">Primary data source: annual HIV cases, AIDS cases, and deaths in Cuba from 1986-2000.</div>
    </li>
  </ul>

  <!-- Senegal Yellow Fever Project -->
  <h2 class="mt-5 mb-3" style="border-bottom: 2px solid #8e5e3b; padding-bottom: 0.5rem;">Senegal Yellow Fever Outbreak (2002)</h2>
  <p class="text-muted">SEIR model with vaccination intervention and parameter estimation.</p>
  
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Barnet, E. D. (2007).</strong>
      <a href="https://doi.org/10.1086/511869" target="_blank" rel="noopener noreferrer">
        <em>Yellow fever: epidemiology and prevention</em>
      </a>.
      Clinical Infectious Diseases, 44(6). 850-856.
      <div class="text-muted small ms-3">Overview of yellow fever epidemiology and transmission dynamics.</div>
    </li>

    <li class="mb-3">
      <strong>Garske, T., Van Kerkhove, M. D., Yactayo, S., Ronveaux, O., Lewis, R. F., Staples, J. E., ... & Ferguson, N. M. (2014).</strong>
      <a href="https://doi.org/10.1371/journal.pmed.1001638" target="_blank" rel="noopener noreferrer">
        <em>Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data</em>
      </a>.
      PLoS Medicine, 11(5), e1001638.
      <div class="text-muted small ms-3">Infectious period estimates and vaccination impact assessment methodology.</div>
    </li>
    
    <li class="mb-3">
      <strong>Monath, T. P. (2012).</strong>
      <a href="https://doi.org/10.1016/j.jcv.2014.08.030" target="_blank" rel="noopener noreferrer">
        <em>Review of the risks and benefits of yellow fever vaccination including some new analyses</em>
      </a>.
      Expert Review of Vaccines, 11(4), 427-448.
      <div class="text-muted small ms-3">Vaccine efficacy data and safety profile.</div>
    </li>
    
    <li class="mb-3">
      <strong>Monath, T. P. & Vasconcelos, P. F. (2015).</strong>
      <a href="https://doi.org/10.1016/j.jcv.2014.08.030" target="_blank" rel="noopener noreferrer">
        <em>Yellow Fever</em>
      </a>.
      Journal of Clinical Virology, 64, 160-173.
      <div class="text-muted small ms-3">Comprehensive review of clinical parameters including incubation period (6 days).</div>
    </li>

    <li class="mb-3">
      <strong>Staples, J. E., Gershman, M., & Fischer, M. (2010).</strong>
      <a href="https://pubmed.ncbi.nlm.nih.gov/20671663/" target="_blank" rel="noopener noreferrer">
        <em>Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)</em>
      </a>.
      MMWR Recommendations and Reports, 59(RR-7), 1-27.
      <div class="text-muted small ms-3">CDC vaccine guidelines and efficacy standards (≥95%).</div>
    </li>

    <li class="mb-3">
      <strong>World Health Organization (2023).</strong>
      <a href="https://www.who.int/news-room/fact-sheets/detail/yellow-fever" target="_blank" rel="noopener noreferrer">
        <em>Yellow Fever</em>
      </a>.
      WHO Fact Sheets.
      <div class="text-muted small ms-3">Current epidemiology, outbreak data, and prevention strategies.</div>
    </li>
  </ul>

  <!-- Measles ABM Project -->
  <h2 class="mt-5 mb-3" style="border-bottom: 2px solid #8e5e3b; padding-bottom: 0.5rem;">Measles Agent-Based Model in Schools</h2>
  <p class="text-muted">Individual-level simulation of measles transmission with spatial structure and vaccination clustering.</p>
  
  <h3 class="mt-4 mb-2 h5">Epidemiological Parameters</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Centers for Disease Control and Prevention (CDC).</strong>
      <a href="https://www.cdc.gov/measles/hcp/index.html" target="_blank" rel="noopener noreferrer">
        <em>Measles (Rubeola): For Healthcare Professionals</em>
      </a>.
      CDC Website.
      <div class="text-muted small ms-3">MMR vaccine efficacy (97% with 2 doses), infectious period (8 days), clinical parameters.</div>
    </li>

    <li class="mb-3">
      <strong>Guerra, F. M., Bolotin, S., Lim, G., Heffernan, J., Deeks, S. L., Li, Y., & Crowcroft, N. S. (2017).</strong>
      <a href="https://doi.org/10.1016/S1473-3099(17)30307-9" target="_blank" rel="noopener noreferrer">
        <em>The basic reproduction number (R₀) of measles: a systematic review</em>
      </a>.
      The Lancet Infectious Diseases, 17(12), e420-e428.
      <div class="text-muted small ms-3">Systematic review of R₀ estimates (12-18), latent period (~10 days), transmissibility parameters.</div>
    </li>

    <li class="mb-3">
      <strong>Phadke, V. K., Bednarczyk, R. A., Salmon, D. A., & Omer, S. B. (2016).</strong>
      <a href="https://doi.org/10.1001/jama.2016.1353" target="_blank" rel="noopener noreferrer">
        <em>Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States</em>
      </a>.
      JAMA, 315(11), 1149-1158.
      <div class="text-muted small ms-3">Evidence for vaccine refusal clustering and outbreak risk in undervaccinated communities.</div>
    </li>

    <li class="mb-3">
      <strong>World Health Organization (2017).</strong>
      <a href="https://www.who.int/publications/i/item/who-wer9217-205-227" target="_blank" rel="noopener noreferrer">
        <em>Measles vaccines: WHO position paper – April 2017</em>
      </a>.
      Weekly Epidemiological Record, 92(17), 205-228.
      <div class="text-muted small ms-3">WHO vaccine efficacy standards, global epidemiology context, herd immunity thresholds.</div>
    </li>
  </ul>

  <h3 class="mt-4 mb-2 h5">Contact Network Studies</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Read, J. M., Edmunds, W. J., Riley, S., Lessler, J., & Cummings, D. A. (2012).</strong>
      <a href="https://doi.org/10.1017/S0950268812000842" target="_blank" rel="noopener noreferrer">
        <em>Close encounters of the infectious kind: methods to measure social mixing behaviour</em>
      </a>.
      Epidemiology & Infection, 140(12), 2117-2130.
      <div class="text-muted small ms-3">Contact pattern measurement methodology, within-classroom vs between-classroom mixing ratios.</div>
    </li>

    <li class="mb-3">
      <strong>Stehlé, J., Voirin, N., Barrat, A., Cattuto, C., Isella, L., Pinton, J. F., ... & Vanhems, P. (2011).</strong>
      <a href="https://doi.org/10.1371/journal.pone.0023176" target="_blank" rel="noopener noreferrer">
        <em>High-resolution measurements of face-to-face contact patterns in a primary school</em>
      </a>.
      PLOS ONE, 6(8), e23176.
      <div class="text-muted small ms-3">Empirical contact network data from primary schools: ~20 within-classroom contacts/day, contact duration distributions.</div>
    </li>
  </ul>

  <h3 class="mt-4 mb-2 h5">Agent-Based Modeling Methodology</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Ferguson, N. M., Cummings, D. A., Fraser, C., Cajka, J. C., Cooley, P. C., & Burke, D. S. (2006).</strong>
      <a href="https://doi.org/10.1038/nature04795" target="_blank" rel="noopener noreferrer">
        <em>Strategies for mitigating an influenza pandemic</em>
      </a>.
      Nature, 442(7101), 448-452.
      <div class="text-muted small ms-3">Large-scale ABM implementation for pandemic planning, school closure intervention modeling.</div>
    </li>

    <li class="mb-3">
      <strong>Halloran, M. E., Longini Jr, I. M., Nizam, A., & Yang, Y. (2002).</strong>
      <a href="https://doi.org/10.1126/science.1074674" target="_blank" rel="noopener noreferrer">
        <em>Containing bioterrorist smallpox</em>
      </a>.
      Science, 298(5597), 1428-1432.
      <div class="text-muted small ms-3">Foundational work on ABM for vaccine-preventable diseases, intervention strategy evaluation.</div>
    </li>

    <li class="mb-3">
      <strong>Kerr, C. C., Stuart, R. M., Mistry, D., Abeysuriya, R. G., Rosenfeld, K., Hart, G. R., ... & Klein, D. J. (2021).</strong>
      <a href="https://doi.org/10.1371/journal.pcbi.1009149" target="_blank" rel="noopener noreferrer">
        <em>Covasim: an agent-based model of COVID-19 dynamics and interventions</em>
      </a>.
      PLOS Computational Biology, 17(7), e1009149.
      <div class="text-muted small ms-3">Modern ABM framework demonstrating network structure, stochastic dynamics, and intervention testing.</div>
    </li>

    <li class="mb-3">
      <strong>Willem, L., Verelst, F., Bilcke, J., Hens, N., & Beutels, P. (2017).</strong>
      <a href="https://doi.org/10.1186/s12879-017-2699-8" target="_blank" rel="noopener noreferrer">
        <em>Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015)</em>
      </a>.
      BMC Infectious Diseases, 17(1), 612.
      <div class="text-muted small ms-3">Comprehensive review of ABM best practices, validation approaches, and methodological standards.</div>
    </li>
  </ul>

  <!-- Vaccination Economics Project -->
  <h2 class="mt-5 mb-3" style="border-bottom: 2px solid #8e5e3b; padding-bottom: 0.5rem;">Behavioral Economics of Childhood Vaccination</h2>
  <p class="text-muted">SEIR-V compartmental model with game-theoretic decision-making and cost-effectiveness analysis.</p>
  
  <h3 class="mt-4 mb-2 h5">Game Theory & Vaccination Behavior</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Bauch, C. T., & Earn, D. J. D. (2004).</strong>
      <a href="https://doi.org/10.1073/pnas.0403823101" target="_blank" rel="noopener noreferrer">
        <em>Vaccination and the theory of games</em>
      </a>.
      Proceedings of the National Academy of Sciences, 101(36), 13391-13394.
      <div class="text-muted small ms-3">Foundational paper on game-theoretic vaccination models; demonstrates Nash equilibrium below herd immunity threshold due to free-rider problem.</div>
    </li>

    <li class="mb-3">
      <strong>Bauch, C. T. (2005).</strong>
      <a href="https://doi.org/10.1098/rspb.2005.3153" target="_blank" rel="noopener noreferrer">
        <em>Imitation dynamics predict vaccinating behaviour</em>
      </a>.
      Proceedings of the Royal Society B: Biological Sciences, 272(1573), 1669-1675.
      <div class="text-muted small ms-3">Extends static game theory with dynamic learning; shows how vaccine coverage oscillates over time through social imitation.</div>
    </li>

    <li class="mb-3">
      <strong>Bauch, C. T., & Bhattacharyya, S. (2012).</strong>
      <a href="https://doi.org/10.1371/journal.pcbi.1002452" target="_blank" rel="noopener noreferrer">
        <em>Evolutionary game theory and social learning can determine how vaccine scares unfold</em>
      </a>.
      PLOS Computational Biology, 8(4), e1002452.
      <div class="text-muted small ms-3">Validates behavior-incidence models against UK pertussis and MMR vaccine scares; demonstrates strategic interactions drive vaccinating behavior.</div>
    </li>
  </ul>

  <h3 class="mt-4 mb-2 h5">Economic Analysis & Nash vs. Utilitarian Optima</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Galvani, A. P., Reluga, T. C., & Chapman, G. B. (2007).</strong>
      <a href="https://doi.org/10.1073/pnas.0606774104" target="_blank" rel="noopener noreferrer">
        <em>Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum</em>
      </a>.
      Proceedings of the National Academy of Sciences, 104(13), 5692-5697.
      <div class="text-muted small ms-3">Key paper comparing Nash equilibrium (individual self-interest) vs. utilitarian optimum (social welfare); shows CDC policy aligns with individual behavior rather than optimal public health outcomes.</div>
    </li>

    <li class="mb-3">
      <strong>World Health Organization (2008).</strong>
      <a href="https://iris.who.int/handle/10665/69981" target="_blank" rel="noopener noreferrer">
        <em>WHO Guide for standardization of economic evaluations of immunisation programmes</em>
      </a>.
      WHO Document Production Services.
      <div class="text-muted small ms-3">Standard methodology for vaccine cost-effectiveness analysis; defines ICER calculation, discount rates (3%), and GDP-based thresholds.</div>
    </li>

    <li class="mb-3">
      <strong>Robinson, L. A., Hammitt, J. K., Chang, A. Y., & Resch, S. (2017).</strong>
      <a href="https://doi.org/10.1371/journal.pone.0168512" target="_blank" rel="noopener noreferrer">
        <em>Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds</em>
      </a>.
      PLOS ONE, 11(12), e0168512.
      <div class="text-muted small ms-3">Systematic review of DALY-based cost-effectiveness studies; validates WHO threshold methodology and discount rate standards.</div>
    </li>
  </ul>

  <h3 class="mt-4 mb-2 h5">Vaccine Hesitancy Framework</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>MacDonald, N. E., & SAGE Working Group on Vaccine Hesitancy (2015).</strong>
      <a href="https://doi.org/10.1016/j.vaccine.2015.04.036" target="_blank" rel="noopener noreferrer">
        <em>Vaccine hesitancy: Definition, scope and determinants</em>
      </a>.
      Vaccine, 33(34), 4161-4164.
      <div class="text-muted small ms-3">WHO SAGE official definition of vaccine hesitancy; introduces the "3 C's" model (Confidence, Complacency, Convenience).</div>
    </li>

    <li class="mb-3">
      <strong>World Health Organization (2014).</strong>
      <a href="https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf" target="_blank" rel="noopener noreferrer">
        <em>Report of the SAGE Working Group on Vaccine Hesitancy</em>
      </a>.
      WHO Strategic Advisory Group of Experts on Immunization.
      <div class="text-muted small ms-3">Comprehensive determinants matrix categorizing contextual, individual/group, and vaccine-specific influences on hesitancy.</div>
    </li>

    <li class="mb-3">
      <strong>Dubé, E., Laberge, C., Guay, M., Bramadat, P., Roy, R., & Bettinger, J. A. (2013).</strong>
      <a href="https://doi.org/10.1016/j.vaccine.2013.08.042" target="_blank" rel="noopener noreferrer">
        <em>Vaccine hesitancy: an overview</em>
      </a>.
      Human Vaccines & Immunotherapeutics, 9(8), 1763-1773.
      <div class="text-muted small ms-3">Review of psychological and social factors driving vaccine hesitancy; discusses risk perception, trust, and information processing.</div>
    </li>
  </ul>

  <h3 class="mt-4 mb-2 h5">Measles Epidemiology & Economics</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Guerra, F. M., Bolotin, S., Lim, G., Heffernan, J., Deeks, S. L., Li, Y., & Crowcroft, N. S. (2017).</strong>
      <a href="https://doi.org/10.1016/S1473-3099(17)30307-9" target="_blank" rel="noopener noreferrer">
        <em>The basic reproduction number (R₀) of measles: a systematic review</em>
      </a>.
      The Lancet Infectious Diseases, 17(12), e420-e428.
      <div class="text-muted small ms-3">Systematic review establishing R₀ range (12-18), latent period (~10 days), infectious period (~8 days); critical for SEIR-V parameterization.</div>
    </li>

    <li class="mb-3">
      <strong>Centers for Disease Control and Prevention (CDC).</strong>
      <a href="https://www.cdc.gov/measles/hcp/index.html" target="_blank" rel="noopener noreferrer">
        <em>Measles (Rubeola): For Healthcare Professionals</em>
      </a>.
      CDC Website.
      <div class="text-muted small ms-3">Vaccine efficacy (93% first dose, 97% two doses), case fatality rate (0.1-0.2% in developed countries), complication rates.</div>
    </li>

    <li class="mb-3">
      <strong>Zhou, F., Shefer, A., Wenger, J., Messonnier, M., Wang, L. Y., Lopez, A., ... & Seward, J. F. (2014).</strong>
      <a href="https://doi.org/10.1542/peds.2013-0518" target="_blank" rel="noopener noreferrer">
        <em>Economic evaluation of the routine childhood immunization program in the United States, 2009</em>
      </a>.
      Pediatrics, 133(4), 577-585.
      <div class="text-muted small ms-3">Cost-benefit analysis showing $13.50 saved per $1 spent on MMR vaccine; source for vaccination and treatment cost parameters.</div>
    </li>

    <li class="mb-3">
      <strong>Atwell, J. E., Van Otterloo, J., Zipprich, J., Winter, K., Harriman, K., Salmon, D. A., ... & Omer, S. B. (2013).</strong>
      <a href="https://doi.org/10.1001/jamapediatrics.2013.455" target="_blank" rel="noopener noreferrer">
        <em>Nonmedical vaccine exemptions and pertussis in California, 2010</em>
      </a>.
      JAMA Pediatrics, 167(10), 929-934.
      <div class="text-muted small ms-3">Demonstrates link between vaccine refusal clustering and outbreak risk; motivates spatial heterogeneity in behavioral model.</div>
    </li>
  </ul>

  <h3 class="mt-4 mb-2 h5">DALYs & Health Impact Metrics</h3>
  <ul class="list-unstyled">
    <li class="mb-3">
      <strong>Global Burden of Disease Study 2019.</strong>
      <a href="https://doi.org/10.1016/S0140-6736(20)30925-9" target="_blank" rel="noopener noreferrer">
        <em>Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019</em>
      </a>.
      The Lancet, 396(10258), 1204-1222.
      <div class="text-muted small ms-3">Source for disability weights: measles mild (0.051), moderate (0.133), severe (0.280), complications (0.400).</div>
    </li>

    <li class="mb-3">
      <strong>Salomon, J. A., Haagsma, J. A., Davis, A., de Noordhout, C. M., Polinder, S., Havelaar, A. H., ... & Vos, T. (2015).</strong>
      <a href="https://doi.org/10.1016/S2214-109X(15)00069-8" target="_blank" rel="noopener noreferrer">
        <em>Disability weights for the Global Burden of Disease 2013 study</em>
      </a>.
      The Lancet Global Health, 3(11), e712-e723.
      <div class="text-muted small ms-3">Methodology for deriving disability weights through population surveys; validates GBD weight assignments.</div>
    </li>
  </ul>

</section>
</div>

<script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
</body>
</html>
